Diabetes research and clinical practice

Novel remedial targets accessible for diabetes incorporates Incretin-based treatments (GLP 1 Incretin, DPP4 with GLP 1), oral helpful operators like insulin secretagogues, recovery of pancreatic islet cells and expansion, and cultured microorganism treatments. Embryonic undeveloped cell and fetal antecedent cell transplantations, undifferentiated cell treatments accessible for diabetes. Apart from the above, different computational methodologies in diabetes control, are presented, which are assuming an important part in recognizable proof of qualities bringing about diabetes helping in Early Detection of diabetes. These procedures are likewise valuable in concentrating on the compound etiologist of diabetes revealing different treatment prospects and model development forms for survival expectations.

• Non-invasive diagnostic tool for detecting cardiac disorder in diabetes
• Diabetes and cancer
• Oral therapies: Insulin secretagogues
• Incretin based therapies
• Novel agents within the treatment
• Updates of anti-diabetic agents
• Measurement of insulin resistance and secretion within the diabetes clinic
• Diabetes Case Reports